Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea

CompletedOBSERVATIONAL
Enrollment

397

Participants

Timeline

Start Date

December 28, 2017

Primary Completion Date

November 16, 2023

Study Completion Date

November 16, 2023

Conditions
Multiple Myeloma
Interventions
DRUG

POMALYST® (Pomalidomide)

The recommended starting dose of POMALYST is 4 mg once daily taken orally on Days 1 to 21 of repeated 28-day cycles. The recommended dose of dexamethasone is 40 mg orally once daily on Days 1, 8, 15 and 22 of each 28-day treatment cycle

Trial Locations (33)

14068

Hallym University Sacred Heart Hospital, Anyang

14584

Soonchunhyang University Hospital, Bucheon-si

15355

Korea University Ansan Hospital, Ansan

16499

Ajou Unversity Medical Center, Suwon

22332

Inha University Hospital, Incheon

26426

Wonju Severance Christian Hospital, Wŏnju

35015

Chungnam National University Hospital, Daejeon

41931

Keimyung University Dongsan Medical, Daegu

42415

Yeungnam University Medical Center, Daegu

42472

Daegu Catholic University Medical Center, Daegu

Local Institution - 021, Daegu

44033

Ulsan University Hospital, Ulsan

47932

Inje University Busan Paik Hospital, Busan

48108

Inje University Haeundae Paik Hospital, Busan

49201

Dong-A University Hospital, Busan

49241

Pusan National University Hospital, Busan

49267

Kosin University Gospel Hospital, Busan

50612

Pusan National University Yangsan, Yangsan

52727

Gyeongsang National University Hospital, Jinju

54907

Chonbuk National University Hospital, Jeonju

58128

Chonnam National University Hwasun Hospital, Hwasun

660-702

Local Institution - 024, Jinju

01757

Inje University Sanggye Paik Hospital, Seoul

02841

Korea University Anam Hospital, Seoul

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Seoul

06351

Samsung Medical Center, Seoul

06591

The catholic University of Korea Seoul St. Maty's, Seoul

07061

Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul

07985

Ewha Womans University Medical, Seoul

08308

Korea University Guro Hospital, Seoul

135-710

Local Institution - 001, Seoul

136-705

Local Institution - 002, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY

NCT03288974 - Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea | Biotech Hunter | Biotech Hunter